Abstract 1457P
Background
Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend locally ablative therapy if technically feasible. Still, evidence is lacking to guide the choice of optimal multimodal treatment approaches and their impact on clinical endpoints.
Methods
Electronic medical records and clinical databases (years 2004 – 2022) from two major German comprehensive cancer centers were searched for cases with OMD NSCLC and treatment patterns. Prespecified OMD criteria included presence of ≤5 metastases in ≤2 organ systems, excluding primary tumor and mediastinal lymph nodes. Endpoints of this retrospective analysis were overall survival (OS), disease-free survival (DFS, first-line therapy until recurrence) and time-to-treatment failure (TTF).
Results
A total of 207 patients with OMD NSCLC were identified (46.9% female; median age 60.8; median follow-up 32 months; T1-2 vs. T3-4 51%/49%, N0-1 vs. N2-3 48%/52%, M1a 10.7%, metastases in one organ system 89.7% vs. multiple 10.3%). A dedicated OMD treatment strategy was explicitly specified in 164 patients (79.2%). Locally ablative therapy was applied to all tumor sites in 140 patients (67.6%), including radiotherapy (85%) and/or surgery (73.6%). Median OS of the full analysis cohort was 27.7 months, with 27.2% OS at 5 years. Median OS in patients receiving locally ablative therapy to all NSCLC sites amounted to 33.4 months (5y rate 35.7%) with a median DFS of 10.6 months (11.2% at 5y). First-line therapy included systemic therapy in 167 patients (80.7%), which was associated with doubling of DFS (median 12.2 vs. 6.0 months, p<0.001), and a trend towards improved OS. First-line chemoimmunotherapy was only approved in 2018/2019, thus limiting follow-up in this subgroup. Nevertheless, DFS (HR 0.5, p=0.025, 2y rate 46% vs. 15%) and TTF (HR 0.45, p<0.001) were greatly improved with first-line chemoimmunotherapy vs. chemotherapy.
Conclusions
Patients with OMD NSCLC benefit from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. Although true freedom from recurrence is rare, extended OS can be achieved in a substantial fraction of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Wiesweg: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Takeda, GSK, AstraZeneca; Financial Interests, Personal, Advisory Board: GSK, Novartis, Pfizer, Roche, Janssen, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Takeda; Financial Interests, Institutional, Funding: Bristol Myers Squibb. T. Plönes: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: BMS, Roche, AstraZeneca. M. Metzenmacher: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Novocure, Pfizer, Roche, Takeda. W.E.E. Eberhardt: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Bristol Myers Squibb, MSD, Boehringer Ingelheim, Lilly, Amgen, Takeda, Pfizer, Novartis, Roche, Sanofi, AbbVie; Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Bristol Myers Squibb, MSD, Bayer, Lilly, Boehringer Ingelheim, Takeda, Pfizer, MSD, Novartis, Sanofi, AbbVie, Amgen, Janssen; Financial Interests, Institutional, Research Funding: AstraZeneca, Lilly, Bristol Myers Squibb; Non-Financial Interests, Personal and Institutional, Steering Committee Member: IASLC Staging Committee, M-track. A. Stenzinger: Financial Interests, Personal, Advisory Board: Aignostics, AstraZeneca, Janssen, Bayer, Seattle Genetics, Pfizer, MSD, Eli Lilly, Illumina, Thermo Fisher, Amgen; Financial Interests, Institutional, Advisory Board: BMS, Takeda, Novartis; Financial Interests, Personal, Invited Speaker: Roche, Incyte; Financial Interests, Institutional, Research Grant: Bayer, Chugai, BMS, Incyte. F. Weykamp: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD. M. Thomas: Financial Interests, Personal, Advisory Board: AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Daiichi Sankyo, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda; Financial Interests, Institutional, Research Funding: AstraZeneca, Bristol Myers Squibb, Merck, Roche, Takeda. M.H.H. Schuler: Financial Interests, Personal, Invited Speaker: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, Roche; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb. P. Christopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda, Roche, Daiichi Sankyo; Financial Interests, Personal, Writing Engagement: Gilead; Financial Interests, Personal, Invited Speaker: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Amgen, Novartis, Roche; Financial Interests, Personal, Funding: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20